Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 1 of 2: Normalized growth rate inhibition values - Dataset (ID:20343)

Filter results: >>>>
Cell Small Molecule Small Mol Concentration (uM) Primary Target Pathway Mean Normalized Growth Rate Inhibition Value Increased Fraction Dead
MDA-MB-134-VI INK-128
0.00031623
mTORC1/2
PI3K/mTOR
0.9671 -0.00323
MDA-MB-134-VI Neratinib
0.00031623
EGFR/HER2
RTK
1.3354 0.00352
BT-20 Neratinib
0.00031623
EGFR/HER2
RTK
1.0442 -0.00223
MCF7 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
0.9456 0.00258
BT-549 Palbociclib
0.00031623
CDK4/6
Cell cycle
1.0163 0.00360
MDA-MB-134-VI Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
1.0531 0.00467
MDA-MB-157 Palbociclib
0.00031623
CDK4/6
Cell cycle
0.9482 0.00160
MDA-MB-231 INK-128
0.00031623
mTORC1/2
PI3K/mTOR
0.9572 0.00181
MDA-MB-134-VI Trametinib
0.00031623
MEK
MAPK/nRTK
0.9508 0.00935
HCC1806 Taxol
0.00031623
Chemo
Chemotherapy
1.0636 -0.00191
MDA-MB-134-VI Taxol
0.00031623
Chemo
Chemotherapy
0.5566 0.10198
MDA-MB-134-VI Luminespib
0.00031623
HSP90
Misc
1.3361 -0.01039
MDA-MB-134-VI Volasertib
0.00031623
PLK
Cell cycle
1.4141 0.00230
BT-549 Dinaciclib
0.00031623
pan CDK
Cell cycle
1.0210 -0.00896
MDA-MB-157 Neratinib
0.00031623
EGFR/HER2
RTK
1.0337 0.00251
MDA-MB-134-VI Dinaciclib
0.00031623
pan CDK
Cell cycle
1.0543 -0.01056
BT-549 Doxorubicin
0.00031623
Chemo
Chemotherapy
0.9759 0.00537
MDA-MB-134-VI Palbociclib
0.00031623
CDK4/6
Cell cycle
1.1665 -0.00514
MDA-MB-134-VI Doxorubicin
0.00031623
Chemo
Chemotherapy
1.1909 0.00067
Hs 578T Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
0.9607 0.00174
MDA-MB-361 Taxol
0.00031623
Chemo
Chemotherapy
0.9551 0.00737
BT-549 Taxol
0.00031623
Chemo
Chemotherapy
1.0248 0.00400
MCF 10A Doxorubicin
0.00031623
Chemo
Chemotherapy
0.9818 0.00026
MDA-MB-231 Torin2
0.00031623
mTOR/ATM/ATR
PI3K/mTOR
0.9887 0.00258
MDA-MB-157 Volasertib
0.00031623
PLK
Cell cycle
1.0814 -0.00135